NCT05995782View on ClinicalTrials.gov

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Parkinson Disease PsychosisAmyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

FB418

Oral dose

Trial Locations (1)

03080

RECRUITING

Seoul National University, Seoul

Sponsors
All Listed Sponsors
lead

1ST Biotherapeutics, Inc.

INDUSTRY